WO2003087766A3 - Methods of diagnosing potential for metastasis or developing hepatocellular carcinoma and of identifying therapeutic targets - Google Patents

Methods of diagnosing potential for metastasis or developing hepatocellular carcinoma and of identifying therapeutic targets Download PDF

Info

Publication number
WO2003087766A3
WO2003087766A3 PCT/US2003/010783 US0310783W WO03087766A3 WO 2003087766 A3 WO2003087766 A3 WO 2003087766A3 US 0310783 W US0310783 W US 0310783W WO 03087766 A3 WO03087766 A3 WO 03087766A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hcc
patients
metastasis
hepatocellular carcinoma
Prior art date
Application number
PCT/US2003/010783
Other languages
French (fr)
Other versions
WO2003087766A2 (en
Inventor
Xin Wei Wang
Qing-Hai Ye
Jin Woo Kim
Original Assignee
Us Gov Health & Human Serv
Xin Wei Wang
Qing-Hai Ye
Jin Woo Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Xin Wei Wang, Qing-Hai Ye, Jin Woo Kim filed Critical Us Gov Health & Human Serv
Priority to AU2003230838A priority Critical patent/AU2003230838A1/en
Publication of WO2003087766A2 publication Critical patent/WO2003087766A2/en
Publication of WO2003087766A3 publication Critical patent/WO2003087766A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Evolutionary Computation (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Microbiology (AREA)
  • Bioethics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Software Systems (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Artificial Intelligence (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

The present invention relates to methods for diagnosing the metastatic potential of hepatocellular carcinoma (HCC) in HCC patients and methods for diagnosing the potential of developing HCC in patients with chronic liver diseases. A computer readable medium, a digital computer, and a system useful for such diagnosis are also provided. Further disclosed are methods for identifying potential therapeutic targets for treating metastasis in HCC patients and methods for preventing HCC in patients with chronic liver diseases. In addition, the invention provides methods for inhibiting metastasis in HCC patients by suppressing the function of one therapeutic target, osteopontin, and methods for preventing the development of HCC in patients with chronic liver diseases by suppressing the function of one therapeutic target, EpCAM. Pharmaceutical compositions containing agents capable of inhibiting the functions of osteopontin or EpCAM are also disclosed.
PCT/US2003/010783 2002-04-05 2003-04-04 Methods of diagnosing potential for metastasis or developing hepatocellular carcinoma and of identifying therapeutic targets WO2003087766A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003230838A AU2003230838A1 (en) 2002-04-05 2003-04-04 Methods of diagnosing potential for metastasis or developing hepatocellular carcinoma and of identifying therapeutic targets

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37089502P 2002-04-05 2002-04-05
US60/370,895 2002-04-05

Publications (2)

Publication Number Publication Date
WO2003087766A2 WO2003087766A2 (en) 2003-10-23
WO2003087766A3 true WO2003087766A3 (en) 2004-07-29

Family

ID=29250601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/010783 WO2003087766A2 (en) 2002-04-05 2003-04-04 Methods of diagnosing potential for metastasis or developing hepatocellular carcinoma and of identifying therapeutic targets

Country Status (3)

Country Link
CN (1) CN1659287A (en)
AU (1) AU2003230838A1 (en)
WO (1) WO2003087766A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003226279A1 (en) * 2002-04-08 2003-10-27 Ciphergen Biosystems, Inc. Serum biomarkers in hepatocellular carcinoma
EP1661991A4 (en) * 2003-08-24 2007-10-10 Univ Nihon Hepatocellular cancer-associated gene
JP2007534772A (en) * 2004-04-27 2007-11-29 イルミジェン バイオサイエンシーズ， インコーポレイテッド Methods and compositions for specifically targeting human hepatocellular carcinoma cells
US20060068418A1 (en) * 2004-07-09 2006-03-30 Godfrey Tony E Identification of markers in lung and breast cancer
US20080213269A1 (en) * 2005-02-24 2008-09-04 Hideaki Tojo Preventive and/or Treating Agent for Cancer
WO2007149948A2 (en) 2006-06-20 2007-12-27 The Gov. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for diagnosis and treatment of tumors
DE602007013405D1 (en) 2006-07-14 2011-05-05 Us Government METHOD FOR DETERMINING THE PROGNOSIS OF ADENOCARCINOMA
CN101457254B (en) * 2008-10-09 2011-04-06 北京大学人民医院 Gene chip and kit for liver cancer prognosis
CN101891814B (en) * 2009-05-21 2012-11-07 中国科学院上海生命科学研究院 Anti-osteopontin OPN monoclonal antibody and application thereof
CN101812507B (en) * 2009-12-04 2012-07-04 复旦大学附属中山医院 Gene chip for predicting liver cancer metastasis and recurrence risk and manufacturing method and using method thereof
CN102690784B (en) * 2011-03-22 2015-10-28 上海市肿瘤研究所 The foundation of hepatoma cell line HCC-LY10 and application
CN102507938B (en) * 2011-10-08 2014-12-24 复旦大学附属中山医院 Liver cancer metastasis prognosis quantitative antibody chip and reagent kit
CN102507936B (en) * 2011-11-09 2013-10-23 北京正旦国际科技有限责任公司 Multi-antibody immunomic mass spectrum kit for liver cancer marker
WO2014039718A1 (en) * 2012-09-05 2014-03-13 Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz Methods for discovering therapeutic targets
AU2014274224B2 (en) * 2013-05-28 2016-06-09 Five3 Genomics, Llc Paradigm drug response networks
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
CN103808944B (en) * 2014-03-07 2016-04-20 高平 Biomarker VWF and ADAMTS13 and the purposes in liver cirrhosis diagnosis reagent thereof
US10758886B2 (en) 2015-09-14 2020-09-01 Arizona Board Of Regents On Behalf Of Arizona State University Conditioned surfaces for in situ molecular array synthesis
BR112018009071B1 (en) * 2015-11-06 2021-12-14 Ventana Medical Systems, Inc IN VITRO METHOD TO PREPARE A REPRESENTATIVE SAMPLE FOR ANALYSIS
CN106957893B (en) * 2016-01-11 2020-06-09 中国科学院分子细胞科学卓越创新中心 Tumor immunotherapy drug target and application thereof
EP3532641A4 (en) * 2016-10-28 2020-06-17 Mao Ying Genetech Inc. The primary site of metastatic cancer identification method and system thereof
US20200224277A1 (en) * 2017-07-17 2020-07-16 Mao Ying Genetech Inc. Cell type identification method and system thereof
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
CN109870576B (en) * 2017-12-05 2021-08-10 中国科学院大连化学物理研究所 Application of quantitative detection of USP10 protein in primary liver cancer prognosis judgment kit
KR102180117B1 (en) * 2018-06-14 2020-11-17 가톨릭대학교 산학협력단 Hcc specific biomarkers
CN109234394A (en) * 2018-09-30 2019-01-18 深圳市南山区人民医院 A kind of diagnosing cancer of liver marker and its screening technique
CN109364249B (en) * 2018-11-05 2021-09-24 安徽医科大学 Application of MANF-targeted substance in preparation of product for treating intrahepatic bile duct cancer
CN109632773B (en) * 2019-01-08 2021-11-12 贵州大学 Screening method of dihydrolipoic acid succinyltransferase inhibitor
CN110029168B (en) * 2019-05-09 2020-02-14 山东省立医院 Application of gene FGL1 in preparation of colorectal cancer and lung cancer diagnostic kit and kit
CN110261619B (en) * 2019-06-14 2021-06-25 上海四核生物科技有限公司 Application of PRKAR2B protein as gastric cancer serum biomarker and kit thereof
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
CN110782954B (en) * 2019-10-31 2021-05-04 哈尔滨工业大学 Weight modular mapping method for predicting drug response in cancer cell strain
CN112002374B (en) * 2020-06-14 2022-04-22 北京臻知医学科技有限责任公司 MHC-I epitope affinity prediction method based on deep learning
EP4134454A1 (en) 2020-11-17 2023-02-15 Sansure Biotech Inc. Reagent combination and kit for detecting liver cancers, and use thereof
CN113652480A (en) * 2021-06-28 2021-11-16 武汉大学 Application of CAT in preparation of hepatocellular carcinoma early diagnosis kit and preparation or screening of anti-liver cancer drugs
CN114699405B (en) * 2022-03-15 2023-05-19 四川轻化工大学 Application of compound in preparation of medicine for treating non-alcoholic fatty liver disease
CN115992244B (en) * 2022-11-28 2024-06-04 武汉大学 SART1 effect in liver cancer treatment
CN117238369B (en) * 2023-09-19 2024-04-09 华中科技大学同济医学院附属同济医院 Renal clear cell carcinoma patient prognosis and drug sensitivity assessment model based on gene related to clear cell differentiation
CN118389693B (en) * 2024-06-24 2024-09-17 广州医科大学 Application of ORP9 gene as target spot in screening medicines for preventing and treating liver cell and liver cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175084A (en) * 1987-10-30 1992-12-29 Fuji Yakuhin Kogyo Kabushiki Kaisha Method for the diagnosis of hepatic carcinoma
US6524787B1 (en) * 1999-08-30 2003-02-25 Mary J. C. Hendrix Diagnostics and therapy based on vascular mimicry
US20030211466A1 (en) * 1999-12-28 2003-11-13 Ribonomics, Inc. Methods for identifying functionally related genes and drug targets

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175084A (en) * 1987-10-30 1992-12-29 Fuji Yakuhin Kogyo Kabushiki Kaisha Method for the diagnosis of hepatic carcinoma
US6524787B1 (en) * 1999-08-30 2003-02-25 Mary J. C. Hendrix Diagnostics and therapy based on vascular mimicry
US20030211466A1 (en) * 1999-12-28 2003-11-13 Ribonomics, Inc. Methods for identifying functionally related genes and drug targets

Also Published As

Publication number Publication date
WO2003087766A2 (en) 2003-10-23
AU2003230838A1 (en) 2003-10-27
AU2003230838A8 (en) 2003-10-27
CN1659287A (en) 2005-08-24

Similar Documents

Publication Publication Date Title
WO2003087766A3 (en) Methods of diagnosing potential for metastasis or developing hepatocellular carcinoma and of identifying therapeutic targets
Tangkijvanich et al. Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma
Kubo et al. Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease
Kow et al. Risk factors of peritoneal recurrence and outcome of resected peritoneal recurrence after liver resection in hepatocellular carcinoma: review of 1222 cases of hepatectomy in a tertiary institution
Lee Intrahepatic lymphoepithelioma-like cholangiocarcinoma not associated with epstein-barr virus: a case report
Kim et al. Lamivudine versus entecavir for newly diagnosed hepatitis B virus-related hepatocellular carcinoma
Nakanishi et al. Combined hepatocellular carcinoma and neuroendocrine carcinoma with sarcomatous change of the liver after transarterial chemoembolization
Turdean et al. Current data in clinicopathological characteristics of primary hepatic tumors
Donato et al. A case–control study on family history of liver cancer as a risk factor for hepatocellular carcinoma in North Italy
Aboelenen et al. Right hepatectomy for combined primary neuroendocrine and hepatocellular carcinoma. A case report
Ito et al. Perspectives on the underlying etiology of HCC and its effects on treatment outcomes
Bartlett et al. Acquired ornithine transcarbamylase deficiency in pediatric and adolescent patients with fibrolamellar hepatocellular carcinoma
Moudouni et al. Late metastasis of renal cell carcinoma to the submaxillary gland 10 years after radical nephrectomy
Nouso et al. Evolution of prognostic factors in hepatocellular carcinoma in Japan
Yoo et al. Sigmoid colon metastasis from hepatocellular carcinoma
Kattepur et al. Isolated nasopharyngeal metastasis from hepatocellular carcinoma
Llovet et al. Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma
Ogawa et al. Double cancers in the common bile duct: molecular genetic findings with an analysis of LOH
Shiffman Impact of peginterferon maintenance therapy on the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C virus
Parsa et al. Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function
WO2006069765A3 (en) Secreted polypeptide species involved in multiple sclerosis
Wood et al. Hepatocellular carcinoma metastatic to skin: diagnostic utility of antihuman hepatocyte antibody in combination with albumin in situ hybridization
Pusztaszeri et al. Urothelial carcinoma “nested variant” of renal pelvis and ureter
Asfandiyar et al. Influence of hepatitis C on renal function after liver transplantation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 20038129825

Country of ref document: CN

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP